{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:59:16Z","timestamp":1793642356277,"version":"4.5.1"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001296","name":"PKD Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001296","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003187","name":"NSF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009251","name":"USC WiSE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009251","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DMR BMAT 2132744"],"award-info":[{"award-number":["DMR BMAT 2132744"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["DP2-DK121328"],"award-info":[{"award-number":["DP2-DK121328"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioactive Materials"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.bioactmat.2021.10.018","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T09:39:10Z","timestamp":1634895550000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Clinical progress of nanomedicine-based RNA therapies"],"prefix":"10.1016","volume":"12","author":[{"given":"Siyoung A.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9484-4922","authenticated-orcid":false,"given":"Alysia","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelynn","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ji","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bioactmat.2021.10.018_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4068\/cmj.2020.56.2.87","article-title":"RNA therapy: current status and future potential","volume":"56","author":"Kim","year":"2020","journal-title":"Chonnam Medical Journal"},{"issue":"7","key":"10.1016\/j.bioactmat.2021.10.018_bib2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7150\/thno.35568","article-title":"RNA nanotechnology-mediated cancer immunotherapy","volume":"10","author":"Lin","year":"2020","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.bioactmat.2021.10.018_bib4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-based therapeutic gene delivery by expression-augmenting 3' UTRs identified by cellular library screening","volume":"27","author":"Orlandini von Niessen","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib5","article-title":"Short interfering RNA (siRNA) based Medicines and the future of RNAi therapy: a mini review","volume":"19","author":"Valle","year":"2020","journal-title":"Current Trends in Biomedical Engineering & Biosciences"},{"issue":"4","key":"10.1016\/j.bioactmat.2021.10.018_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/nano7040077","article-title":"siRNA delivery strategies: a comprehensive review of recent developments","volume":"7","author":"Tatiparti","year":"2017","journal-title":"Nanomaterials"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.addr.2020.12.008","article-title":"Non-viral COVID-19 vaccine delivery systems","volume":"169","author":"Park","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.bioactmat.2021.10.018_bib8","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.7150\/thno.8491","article-title":"Functional nanostructures for effective delivery of small interfering RNA therapeutics","volume":"4","author":"Hong","year":"2014","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.bioactmat.2021.10.018_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/genes10020092","article-title":"RNA modifications modulate activation of innate toll-like receptors","volume":"10","author":"Freund","year":"2019","journal-title":"Genes"},{"issue":"49","key":"10.1016\/j.bioactmat.2021.10.018_bib11","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1039\/D0CC01848A","article-title":"Dual-targeting RNA nanoparticles for efficient delivery of polymeric siRNA to cancer cells","volume":"56","author":"Kim","year":"2020","journal-title":"Chem Commun (Camb)"},{"issue":"10","key":"10.1016\/j.bioactmat.2021.10.018_bib12","doi-asserted-by":"crossref","first-page":"12522","DOI":"10.1021\/acsnano.0c07197","article-title":"COVID-19 vaccine frontrunners and their nanotechnology design","volume":"14","author":"Chung","year":"2020","journal-title":"ACS Nano"},{"issue":"33","key":"10.1016\/j.bioactmat.2021.10.018_bib13","doi-asserted-by":"crossref","first-page":"11360","DOI":"10.1002\/anie.201905203","article-title":"Bundling mRNA strands to prepare nano-assemblies with enhanced stability towards RNase for InVivoDelivery","volume":"58","author":"Yoshinaga","year":"2019","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib14","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.2147\/IJN.S169399","article-title":"Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology","volume":"13","author":"Xu","year":"2018","journal-title":"Int. J. Nanomed."},{"issue":"2","key":"10.1016\/j.bioactmat.2021.10.018_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2472630318816668","article-title":"siRNA-conjugated nanoparticles to treat ovarian cancer","volume":"24","author":"Halbur","year":"2019","journal-title":"SLAS Technol"},{"issue":"10","key":"10.1016\/j.bioactmat.2021.10.018_bib16","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1021\/acs.molpharmaceut.0c00618","article-title":"Nanomedicine-based approaches for mRNA delivery","volume":"17","author":"Uchida","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib17","doi-asserted-by":"crossref","first-page":"e2001812","DOI":"10.1002\/adhm.202001812","article-title":"Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery","author":"Ho","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2020.12.032","article-title":"The nanomedicine rush: new strategies for unmet medical needs based on innovative nano DDS","volume":"330","author":"Sato","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/nano10020364","article-title":"Nanomedicines to deliver mRNA: state of the art and future perspectives","volume":"10","author":"G\u00f3mez-Aguado","year":"2020","journal-title":"Nanomaterials"},{"issue":"3","key":"10.1016\/j.bioactmat.2021.10.018_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1039\/C8MD00515J","article-title":"Diversity of PEGylation methods of liposomes and their influence on RNA delivery","volume":"10","author":"Nosova","year":"2019","journal-title":"Medchemcomm"},{"issue":"10","key":"10.1016\/j.bioactmat.2021.10.018_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nature Reviews Materials"},{"issue":"6","key":"10.1016\/j.bioactmat.2021.10.018_bib22","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1021\/acs.nanolett.0c01386","article-title":"Deconvoluting lipid nanoparticle structure for messenger RNA delivery","volume":"20","author":"Eygeris","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.actbio.2019.11.022","article-title":"Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles","volume":"102","author":"Sato","year":"2020","journal-title":"Acta Biomater."},{"issue":"9","key":"10.1016\/j.bioactmat.2021.10.018_bib24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib25","first-page":"100991","article-title":"Strategies to deliver RNA by nanoparticles for therapeutic potential","author":"Cox","year":"2021","journal-title":"Mol. Aspect. Med."},{"issue":"5","key":"10.1016\/j.bioactmat.2021.10.018_bib26","article-title":"How drugs are developed and approved by the FDA: current process and future directions","volume":"109","author":"Ciociola","year":"2014","journal-title":"Official journal of the American College of Gastroenterology | ACG"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib27","series-title":"Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation","year":"2018"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib28","series-title":"Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry","year":"2018"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib29","doi-asserted-by":"crossref","first-page":"n1898","DOI":"10.1136\/bmj.n1898","article-title":"FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway","volume":"374","author":"Mahase","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.bioactmat.2021.10.018_bib30","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","article-title":"A decade of FDA-approved drugs (2010\u20132019): trends and future directions","volume":"64","author":"Brown","year":"2021","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioactmat.2021.10.018_bib31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A review of patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib32","article-title":"Paving the road for RNA therapeutics","volume":"41","author":"Dammes","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib33","author":"Agency"},{"issue":"3","key":"10.1016\/j.bioactmat.2021.10.018_bib34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Therapeut."},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"no. 1","key":"10.1016\/j.bioactmat.2021.10.018_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9010065","article-title":"Nanomaterial delivery systems for mRNA vaccines","volume":"9","author":"Buschmann","year":"2021","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.bioactmat.2021.10.018_bib37","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41551-018-0284-0","article-title":"Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA","volume":"2","author":"Islam","year":"2018","journal-title":"Nat Biomed Eng"},{"issue":"13","key":"10.1016\/j.bioactmat.2021.10.018_bib38","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1016\/j.celrep.2017.03.014","article-title":"Coordinated pulses of mRNA and of protein translation or degradation produce EGF-induced protein bursts","volume":"18","author":"Golan-Lavi","year":"2017","journal-title":"Cell Rep."},{"issue":"40","key":"10.1016\/j.bioactmat.2021.10.018_bib39","doi-asserted-by":"crossref","first-page":"17556","DOI":"10.1002\/ange.202007111","article-title":"Phosphorothioate modification of mRNA accelerates the rate of translation initiation to provide more efficient protein synthesis","volume":"132","author":"Kawaguchi","year":"2020","journal-title":"Angew. Chem."},{"issue":"27","key":"10.1016\/j.bioactmat.2021.10.018_bib40","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bioactmat.2021.10.018_bib41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib42","doi-asserted-by":"crossref","first-page":"101142","DOI":"10.1016\/j.nantod.2021.101142","article-title":"Role of nanotechnology behind the success of mRNA vaccines for COVID-19","author":"Khurana","year":"2021","journal-title":"Nano Today"},{"issue":"34","key":"10.1016\/j.bioactmat.2021.10.018_bib43","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib44","first-page":"2020","article-title":"A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates","author":"Vogel","year":"2020","journal-title":"bioRxiv"},{"issue":"3","key":"10.1016\/j.bioactmat.2021.10.018_bib45","first-page":"1663","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"555","key":"10.1016\/j.bioactmat.2021.10.018_bib46","doi-asserted-by":"crossref","first-page":"eabc9396","DOI":"10.1126\/scitranslmed.abc9396","article-title":"An <em>Alphavirus<\/em>-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates","volume":"12","author":"Erasmus","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.bioactmat.2021.10.018_bib47","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bioactmat.2021.10.018_bib48","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3390\/v12121371","article-title":"A glimmer of hope: recent updates and future challenges in zika vaccine development","volume":"12","author":"Castanha","year":"2020","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.bioactmat.2021.10.018_bib49","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-017-0032-6","article-title":"Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines","volume":"2","author":"Lutz","year":"2017","journal-title":"npj Vaccines"},{"issue":"3","key":"10.1016\/j.bioactmat.2021.10.018_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: an update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioengineering & translational medicine"},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expet Rev. Vaccine"},{"issue":"2","key":"10.1016\/j.bioactmat.2021.10.018_bib53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized cancer vaccines: clinical landscape, challenges, and opportunities","volume":"29","author":"Shemesh","year":"2021","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"6382","key":"10.1016\/j.bioactmat.2021.10.018_bib55","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bioactmat.2021.10.018_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040841","article-title":"The promise and challenges of developing miRNA-based therapeutics for Parkinson's disease","volume":"9","author":"Titze-de-Almeida","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.bioactmat.2021.10.018_bib57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/wrna.1114","article-title":"MicroRNA degradation and turnover: regulating the regulators","volume":"3","author":"Zhang","year":"2012","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"9","key":"10.1016\/j.bioactmat.2021.10.018_bib58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41580-019-0164-9","article-title":"Insights into the kinetics of microRNA biogenesis and turnover","volume":"20","author":"Zlotorynski","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.bioactmat.2021.10.018_bib59","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MNH.0000000000000333","article-title":"Therapeutic microRNAs in polycystic kidney disease","volume":"26","author":"Yheskel","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"40","key":"10.1016\/j.bioactmat.2021.10.018_bib60","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.1039\/C8TB01932K","article-title":"Enzymatically synthesized poly(amino-co-ester) polyplexes for systemic delivery of pcDNA-miRNA-214 to suppress colorectal cancer liver metastasis","volume":"6","author":"Luo","year":"2018","journal-title":"J. Mater. Chem. B"},{"issue":"3","key":"10.1016\/j.bioactmat.2021.10.018_bib61","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/jnc.13507","article-title":"miR-186 is decreased in aged brain and suppresses BACE1 expression","volume":"137","author":"Kim","year":"2016","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.bioactmat.2021.10.018_bib62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.17305\/bjbms.2018.2376","article-title":"MicroRNA-466 (miR-466) functions as a tumor suppressor and prognostic factor in colorectal cancer (CRC)","volume":"18","author":"Tong","year":"2018","journal-title":"Bosn. J. Basic Med. Sci."},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib63","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/s41598-019-38566-y","article-title":"Anti-microRNA screen uncovers miR-17 family within miR-17\u223c92 cluster as the primary driver of kidney cyst growth","volume":"9","author":"Yheskel","year":"2019","journal-title":"Sci. Rep."},{"issue":"No 5","key":"10.1016\/j.bioactmat.2021.10.018_bib64","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.27894","article-title":"Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology","volume":"12","author":"Telford","year":"2021","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bioactmat.2021.10.018_bib65","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ymthe.2018.11.018","article-title":"mRNA-based protein replacement therapy for the heart","volume":"27","author":"Magadum","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib66","series-title":"Propionic Acidemia","author":"Shchelochkov","year":"2016"},{"issue":"12","key":"10.1016\/j.bioactmat.2021.10.018_bib67","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib68","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1038\/s41467-020-19156-3","article-title":"Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib69","first-page":"733","article-title":"Anti-HSP47 siRNA lipid nanoparticle ND-L02-s0201 reverses interstitial pulmonary fibrosis in preclinical rat models","author":"Liu","year":"2021","journal-title":"ERJ Open Research"},{"issue":"5","key":"10.1016\/j.bioactmat.2021.10.018_bib70","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1172\/JCI66369","article-title":"Hepatic stellate cells in liver development, regeneration, and cancer","volume":"123","author":"Yin","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/btm2.10003","article-title":"Nanoparticles in the clinic","volume":"1","author":"Anselmo","year":"2016","journal-title":"Bioengineering & translational medicine"},{"issue":"5","key":"10.1016\/j.bioactmat.2021.10.018_bib72","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1158\/1535-7163.MCT-16-0613","article-title":"Lipid nanoparticle\u2013mediated delivery of anti-miR-17 family oligonucleotide suppresses hepatocellular carcinoma growth","volume":"16","author":"Huang","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib73","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jare.2020.08.012","article-title":"Therapeutic advances of miRNAs: a preclinical and clinical update","volume":"28","author":"Chakraborty","year":"2021","journal-title":"J. Adv. Res."},{"issue":"6","key":"10.1016\/j.bioactmat.2021.10.018_bib74","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2217\/nnm-2017-0317","article-title":"The ability of liposomes, tailored for blood-brain barrier targeting, to reach the brain is dramatically affected by the disease state","volume":"13","author":"Magro","year":"2018","journal-title":"Nanomedicine"},{"issue":"50","key":"10.1016\/j.bioactmat.2021.10.018_bib75","doi-asserted-by":"crossref","first-page":"82889","DOI":"10.18632\/oncotarget.12658","article-title":"Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer","volume":"7","author":"Takai","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bioactmat.2021.10.018_bib76","doi-asserted-by":"crossref","first-page":"e10213","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioengineering & Translational Medicine"},{"issue":"7089","key":"10.1016\/j.bioactmat.2021.10.018_bib77","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature04688","article-title":"RNAi-mediated gene silencing in non-human primates","volume":"441","author":"Zimmermann","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib78","series-title":"Translate Bio Pipeline Program Update","year":"2019"},{"issue":"31","key":"10.1016\/j.bioactmat.2021.10.018_bib79","doi-asserted-by":"crossref","first-page":"11449","DOI":"10.1073\/pnas.1411393111","article-title":"Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA","volume":"111","author":"Zuckerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"10.1016\/j.bioactmat.2021.10.018_bib80","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib81","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/mt.2015.193","article-title":"Myocardial delivery of lipidoid nanoparticle carrying modRNA induces rapid and transient expression","volume":"24","author":"Turnbull","year":"2016","journal-title":"Mol. Ther. : the journal of the American Society of Gene Therapy"},{"issue":"10","key":"10.1016\/j.bioactmat.2021.10.018_bib82","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib83","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jconrel.2019.06.042","article-title":"Non-viral delivery of chemically modified mRNA to the retina: subretinal versus intravitreal administration","volume":"307","author":"Devoldere","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib84","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2019.04.015","article-title":"Lipid nanoparticles for delivery of messenger RNA to the back of the eye","volume":"303","author":"Patel","year":"2019","journal-title":"J. Contr. Release"},{"issue":"11","key":"10.1016\/j.bioactmat.2021.10.018_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12111042","article-title":"Aerosolizable lipid nanoparticles for pulmonary delivery of mRNA through design of experiments","volume":"12","author":"Zhang","year":"2020","journal-title":"Pharmaceutics"},{"issue":"477","key":"10.1016\/j.bioactmat.2021.10.018_bib86","doi-asserted-by":"crossref","first-page":"eaat9143","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36\u03b3, and OX40L mRNAs","volume":"11","author":"Hewitt Susannah","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.bioactmat.2021.10.018_bib87","first-page":"882","article-title":"Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity","volume":"1","author":"Li","year":"2020","journal-title":"Nat. Can."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib88","first-page":"464","article-title":"Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: design of a phase 2a clinical trial","volume":"18","author":"Anttila","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bioactmat.2021.10.018_bib89","first-page":"330","article-title":"Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 Week post-myocardial infarction in swine","volume":"9","author":"Carlsson","year":"2018","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.bioactmat.2021.10.018_bib90","first-page":"358","article-title":"Long-term storage of lipid-like nanoparticles for mRNA delivery","volume":"5","author":"Zhao","year":"2020","journal-title":"Bioact Mater"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib91","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/abd816","article-title":"Gold nanoparticle-based nanoprobes with enhanced tumor targeting and photothermal\/photodynamic response for therapy of osteosarcoma","volume":"32","author":"Xiong","year":"2021","journal-title":"Nanotechnology"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib92","doi-asserted-by":"crossref","first-page":"111378","DOI":"10.1016\/j.colsurfb.2020.111378","article-title":"Mannose-functionalized antigen nanoparticles for targeted dendritic cells, accelerated endosomal escape and enhanced MHC-I antigen presentation","volume":"197","author":"Pei","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"3","key":"10.1016\/j.bioactmat.2021.10.018_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21031066","article-title":"The clustering of mApoE anti-amyloidogenic peptide on nanoparticle surface does not alter its performance in controlling beta-amyloid aggregation","volume":"21","author":"Corti","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bioactmat.2021.10.018_bib94","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/1061186X.2016.1258566","article-title":"Trileucine residues in a ligand-CPP-based siRNA delivery platform improve endosomal escape of siRNA","volume":"25","author":"Ullah","year":"2017","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.bioactmat.2021.10.018_bib95","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4155\/tde-2018-0061","article-title":"Developing small activating RNA as a therapeutic: current challenges and promises","volume":"10","author":"Kwok","year":"2019","journal-title":"Ther. Deliv."},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib96","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1261\/rna.2150806","article-title":"Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2\/eIF2C2-dependent activity","volume":"12","author":"Kraynack","year":"2006","journal-title":"RNA (New York, N.Y.)"},{"issue":"9","key":"10.1016\/j.bioactmat.2021.10.018_bib97","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","article-title":"siRNA function in RNAi: a chemical modification analysis","volume":"9","author":"Chiu","year":"2003","journal-title":"RNA (New York, N.Y.)"},{"key":"10.1016\/j.bioactmat.2021.10.018_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020212","article-title":"Investigating the impact of delivery system design on the efficacy of self-amplifying RNA vaccines","volume":"8","author":"Anderluzzi","year":"2020","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib99","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12929-019-0523-z","article-title":"The emerging roles and functions of circular RNAs and their generation","volume":"26","author":"Yu","year":"2019","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.bioactmat.2021.10.018_bib100","doi-asserted-by":"crossref","DOI":"10.1186\/s41544-019-0046-5","article-title":"Circular RNA: functions, applications and prospects","volume":"2","author":"Lu","year":"2020","journal-title":"ExRNA"},{"issue":"2","key":"10.1016\/j.bioactmat.2021.10.018_bib101","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00280-013-2361-0","article-title":"A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors","volume":"73","author":"Tolcher","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.bioactmat.2021.10.018_bib102","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.molmed.2016.10.009","article-title":"Small RNA modifications: integral to function and disease","volume":"22","author":"Zhang","year":"2016","journal-title":"Trends Mol. Med."},{"issue":"12","key":"10.1016\/j.bioactmat.2021.10.018_bib103","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."}],"container-title":["Bioactive Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X21004825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X21004825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T16:01:57Z","timestamp":1762531317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452199X21004825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":103,"alternative-id":["S2452199X21004825"],"URL":"https:\/\/doi.org\/10.1016\/j.bioactmat.2021.10.018","relation":{},"ISSN":["2452-199X"],"issn-type":[{"value":"2452-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical progress of nanomedicine-based RNA therapies","name":"articletitle","label":"Article Title"},{"value":"Bioactive Materials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioactmat.2021.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}